EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Lineage Cell Therapeutics, Inc. (LCTX) had EBIT Margin of -440.17% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$1.73M |
|
$-4.81M |
|
-- |
|
$1.73M |
|
$9.32M |
|
$-7.59M |
|
$2.80M |
|
$-4.79M |
|
$-4.79M |
|
$-4.79M |
|
$-4.79M |
|
$-4.79M |
|
$-4.79M |
|
$-7.59M |
|
$-7.41M |
|
245.03M |
|
261.18M |
|
$-0.02 |
|
$-0.03 |
|
| Balance Sheet Financials | |
$56.16M |
|
$2.50M |
|
$53.37M |
|
$109.53M |
|
$8.15M |
|
$0.02M |
|
$48.69M |
|
$56.84M |
|
$52.70M |
|
$10.32M |
|
$52.70M |
|
249.30M |
|
| Cash Flow Statement Financials | |
$-8.08M |
|
$-2.33M |
|
$5.56M |
|
$41.32M |
|
$36.48M |
|
$-4.85M |
|
$1.17M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.89 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
100.00% |
|
-440.17% |
|
|
EBIT Margin |
-440.17% |
-- |
|
-277.62% |
|
-278.96% |
|
$-8.13M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
2.14 |
|
42.05 |
|
-9.09% |
|
-46.39% |
|
-4.37% |
|
-9.08% |
|
$0.21 |
|
$-0.03 |
|
$-0.03 |
|